« Return to News | R&D Trends | Drug Sponsors

NanoBio, Merk collaborate in RSV research

Friday, December 9, 2011 09:30 AM

NanoBio has formed a preclinical collaboration with a subsidiary of Merck, focused on the development of a vaccine for Respiratory Syncytial Virus (RSV). The studies will evaluate the combination of Merck’s proprietary RSV antigen with NanoBio’s NanoStat adjuvant technology for use as an intranasal vaccine. As part of the agreement, Merck has the option to negotiate a non-exclusive license to the NanoStat adjuvant for development of a commercial RSV vaccine.

Earlier preclinical studies conducted by NanoBio have demonstrated that a NanoStat adjuvanted RSV vaccine induces robust protective immunity, without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail.

RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. Many children develop pulmonary disease and/or asthma from RSV that persists throughout adult life making them susceptible to re-infection. There are currently no approved vaccines for RSV.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.